Article Text

Download PDFPDF
An urgent need to institute COVID-19 testing in patients with IBD experiencing flares
  1. Mohammed Nabil Quraishi1,2,
  2. Rachel Cooney1,
  3. Matthew James Brookes3,
  4. Naveen Sharma1,2
  1. 1 Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  2. 2 University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, United Kingdom
  3. 3 Department of Gastroenterology, New Cross Hospital, Wolverhampton, UK
  1. Correspondence to Dr Mohammed Nabil Quraishi, Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham B12 2TT, UK; M.N.Quraishi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We are facing unprecedented challenges during the current coronavirus disease 2019 (COVID-19) pandemic. Management of chronic diseases requiring immunosuppression, such as inflammatory bowel disease (IBD), during this time period has led to difficult and exceptional decision making by both healthcare providers and patients. Decisions with regard to starting or continuing immunosuppression in IBD in both COVID-19 confirmed and suspected patients are done on a case-by-case basis based on pragmatism and experience drawn from other infections. However, our knowledge of COVID-19 is evolving. Rapid mobilisation of efforts globally has led to expert recommendations by various medical societies to help guide clinicians.1 2 Furthermore, through commendable efforts made by the IBD community through international …

View Full Text


  • Contributors All authors contributed equally to this opinion piece.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.